TY  - JOUR
AU  - Martin, M
AU  - Loibl, S
AU  - Hyslop, T
AU  - De la Haba-Rodriguez, J
AU  - Aktas, B
AU  - Cirrincione, C T
AU  - Mehta, K
AU  - Barry, W T
AU  - Morales, S
AU  - Carey, L A
AU  - Garcia-Saenz, J A
AU  - Partridge, A
AU  - Martinez-Jañez, N
AU  - Hahn, O
AU  - Winer, E
AU  - Guerrero-Zotano, A
AU  - Hudis, C
AU  - Casas, M
AU  - Rodriguez-Martin, C
AU  - Furlanetto, J
AU  - Carrasco, E
AU  - Dickler, M N
PY  - 2019
DO  - 10.1016/j.ejca.2019.06.002
UR  - http://hdl.handle.net/10668/14217
T2  - European journal of cancer (Oxford, England : 1990)
AB  - Randomised trials comparing the efficacy of standard endocrine therapy (ET) versus experimental ET + bevacizumab (Bev) in 1st line hormone receptor-positive patients with metastatic breast cancer have thus far shown conflicting results. We pooled data...
LA  - en
PB  - Elsevier
KW  - Advanced breast cancer
KW  - Bevacizumab
KW  - Endocrine therapy
KW  - Pooled-analysis
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic combined chemotherapy protocols
KW  - Bevacizumab
KW  - Bone neoplasms
KW  - Breast neoplasms
KW  - Evaluation studies as topic
KW  - Female
KW  - Follow-up studies
KW  - Fulvestrant
KW  - Humans
KW  - Letrozole
KW  - Middle aged
KW  - Neoplasm recurrence, local
KW  - Prognosis
KW  - Receptors, estrogen
KW  - Receptors, progesterone
KW  - Soft tissue neoplasms
KW  - Survival rate
KW  - Tamoxifen
TI  - Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
TY  - research article
VL  - 117
ER  -